Effects of Metabolic Risk Factors and Type 1 Diabetes on Brain Glucose and Brain Metabolites

The metabolic syndrome and type 1 diabetes are associated with brain alterations such as cognitive decline brain infarctions, atrophy, and white matter lesions. Despite the importance of these alterations, their pathomechanism is still poorly understood. This study was conducted to investigate brain glucose and metabolites in healthy individuals with an increased cardiovascular risk and in patients with type 1 diabetes in order to discover more information on the nature of the known brain alterations. We studied 43 20- to 45-year-old men. Study I compared two groups of non-diabetic men, one with an accumulation of cardiovascular risk factors and another without. Studies II to IV compared men with type 1 diabetes (duration of diabetes 6.7 ± 5.2 years, no microvascular complications) with non-diabetic men. Brain glucose, N-acetylaspartate (NAA), total creatine (tCr), choline, and myo-inositol (mI) were quantified with proton magnetic resonance spectroscopy in three cerebral regions: frontal cortex, frontal white matter, thalamus, and in cerebellar white matter. Data collection was performed for all participants during fasting glycemia and in a subgroup (Studies III and IV), also during a hyperglycemic clamp that increased plasma glucose concentration by 12 mmol/l. In non-diabetic men, the brain glucose concentration correlated linearly with plasma glucose concentration. The cardiovascular risk group (Study I) had a 13% higher plasma glucose concentration than the control group, but no difference in thalamic glucose content. The risk group thus had lower thalamic glucose content than expected. They also had 17% increased tCr (marker of oxidative metabolism). In the control group, tCr correlated with thalamic glucose content, but in the risk group, tCr correlated instead with fasting plasma glucose and 2-h plasma glucose concentration in the oral glucose tolerance test. Risk factors of the metabolic syndrome, most importantly insulin resistance, may thus influence brain metabolism. During fasting glycemia (Study II), regional variation in the cerebral glucose levels appeared in the non-diabetic subjects but not in those with diabetes. In diabetic patients, excess glucose had accumulated predominantly in the white matter where the metabolite alterations were also the most pronounced. Compared to the controls values, the white matter NAA (marker of neuronal metabolism) was 6% lower and mI (glia cell marker) 20% higher. Hyperglycemia is therefore a potent risk factor for diabetic brain disease and the metabolic brain alterations may appear even before any peripheral microvascular complications are detectable. During acute hyperglycemia (Study III), the increase in cerebral glucose content in the patients with type 1 diabetes was, dependent on brain region, between 1.1 and 2.0 mmol/l. An every-day hyperglycemic episode in a diabetic patient may therefore as much as double brain glucose concentration. While chronic hyperglycemia had led to accumulation of glucose in the white matter, acute hyperglycemia burdened predominantly the gray matter. Acute hyperglycemia also revealed that chronic fluctuation in blood glucose may be associated with alterations in glucose uptake or in metabolism in the thalamus. The cerebellar white matter appeared very differently from the cerebral (Study IV). In the non-diabetic men it contained twice as much glucose as the cerebrum. Diabetes had altered neither its glucose content nor the brain metabolites. The cerebellum seems therefore more resistant to the effects of hyperglycemia than is the cerebrum.

Molecular background of three lethal fetal syndromes

This study identified the molecular defects underlying three lethal fetal syndromes. Lethal Congenital Contracture Syndrome 1 (LCCS1, MIM 253310) and Lethal Arthrogryposis with Anterior Horn Cell Disease (LAAHD, MIM 611890) are fetal motor neuron diseases. They affect the nerve cells that control voluntary muscle movement, and eventually result in severe atrophy of spinal cord motor neurons and fetal immobility. Both LCCS1 and LAAHD are caused by mutations in the GLE1 gene, which encodes for a multifunctional protein involved in posttranscriptional mRNA processing. LCCS2 and LCCS3, two syndromes that are clinically similar to LCCS1, are caused by defective proteins involved in the synthesis of inositol hexakisphosphate (IP6), an essential cofactor of GLE1. This suggests a common mechanism behind these fetal motor neuron diseases, and along with accumulating evidence from genetic studies of more late-onset motor neuron diseases such as Spinal muscular atrophy (SMA) and Amyotrophic lateral sclerosis (ALS), implicates mRNA processing as a common mechanism in motor neuron disease pathogenesis. We also studied gle1-/- zebrafish in order to investigate whether they would be a good model for studying the pathogenesis of LCCS1 and LAAHD. Mutant zebrafish exhibit cell death in their central nervous system at two days post fertilization, and the distribution of mRNA within the cells of mutant zebrafish differs from controls, encouraging further studies. The third lethal fetal syndrome is described in this study for the first time. Cocoon syndrome (MIM 613630) was discovered in a Finnish family with two affected individuals. Its hallmarks are the encasement of the limbs under the skin, and severe craniofacial abnormalities, including the lack of skull bones. We showed that Cocoon syndrome is caused by a mutation in the gene encoding the conserved helix-loop-helix ubiquitous kinase CHUK, also known as IκB kinase α (IKKα). The mutation results in the complete lack of CHUK protein expression. CHUK is a subunit of the IκB kinase enzyme that inhibits NF-κB transcription factors, but in addition, it has an essential, independent role in controlling keratinocyte differentiation, as well as informing morphogenetic events such as limb and skeletal patterning. CHUK also acts as a tumor suppressor, and is frequently inactivated in cancer. This study has brought significant new information about the molecular background of these three lethal fetal syndromes, as well as provided knowledge about the prerequisites of normal human development.

Pienten sokeriyhdisteiden eristäminen ja tunnistus kuusen solususpensioliuoksesta

Biologisesti aktiivisilla oligosakkarideilla on vaikutuksia kasvin kasvuun ja kehittymiseen. Tietyn tyyppiset oligosakkaridit voivat myös indusoida puolustusreaktion valikoivasti oligosakkaridista riippuen. Useat biologisesti aktiiviset oligosakkaridit on löydetty kasvien soluseinää keinotekoisesti hajottamalla. Pro gradu -tutkielman tarkoituksena oli karakterisoida kuusen (Picea abies) solukkolinjan A3/85 solususpensiokasvatukseen erittämiä oligosakkarideja. Kuusisolukko A3/85 on otollinen kandidaatti tutkimukseen, sillä sen on todettu erittävän solunulkoista ligniiniä suspensioliuokseen. Oligosakkarideja karakterisoitiin yhden ja neljän vuorokauden kasvatuksista. Alustan sokeripitoisuutta alennettiin neljän vuorokauden kasvatuksissa karakterisoinnin helpottamiseksi. Oligosakkaridien pitoisuudet voivat olla hyvin alhaisia, joten solujen tuottamia yhdisteitä seurattiin myös radioaktiivisen D-[U-14C]-glukoosin avulla. Kasvien soluseinässä yleiset glukuronihappo, galakturonihappo, ksyloosi, arabinoosi ja apioosi valmistetaan glukoosi-6-fosfaatista, joko myo-inositolihapetusreitin tai sokerihapetusreitin kautta. Lisäksi tutkittiin, muuttuuko radioaktiivisen leiman jakautuminen näytteissä, kun kasvatusliuoksessa on tai ei ole myo-inositolia. Kasvatusliuos fraktioitiin geelisuodatuskromatografialla. Fraktioiden sisältämät yhdisteet eroteltiin paperikromatografialla ja värjättiin hopeanitraatilla, aniliinivetyftalaatilla tai ninhydriinillä. Hopeanitraatti on hyödyllinen monosakkaridien, oligosakkaridien ja alditolien värjäyksessä. Radioaktiivisuuden kertymistä yhdisteisiin seurattiin nestetuikelaskimella ja autoradiografialla. Paperikromatografialla erotelluista yhdisteistä valittiin mielenkiintoiseksi koetut yhdisteet, jotka eristettiin preparatiivisella paperikromatografialla. Eristetyille yhdisteille tehtiin happohydrolysointi, borohydridikäsittely tai entsymaattinen Driselaasi -käsittely. Happohydrolysointi avaa sokeriyksiköiden väliset glykosidiset sidokset. Natriumborohydridipelkistys muuttaa oligosakkaridiketjun pelkistävän sokerin sokerialkoholiksi ja Driselaasi -käsittely avaa isoprimeveroosin Xyl-Į-(1ĺ6)-Glc -sidosta lukuun ottamatta muut glykosidiset sidokset. 14C-leima on jakautunut myo-inositolin kanssa kasvatetun näytteen fraktioinnissa vahvemmin suurimolekyylisiin yhdisteisiin, kun taas ilman myo-inositolia kasvatetussa näytteessä suurin aktiivisuus D-[U-14C]-glukoosin jälkeen on trisakkaridien alueella. Suspensioliuoksista analysoitiin useita oligosakkarideja polymerisaatioasteella 1-4. Analysoiduista yhdisteistä kolme sisälsivät ksyloosia, jota solut voivat syntetoida joko myo-inositolin hapetusreitin tai glukoosin hapetusreitin kautta. Myo-inositolin puuttuminen alustasta lisäsi näiden leimattujen yhdisteiden pitoisuutta. Alustan myo-inositoli ei ole radioaktiivista, joten myo-inositolihapetusreitin kautta valmistetut monosakkaridit eivät näy autoradiografiassa. Vaikuttaisi siis siltä, että myo-inositolihapetusreitti on aktiivinen ainakin, jos solukolle tarjotaan myo-inositolia. Lisätty myo-inositoli vähentää sokerihapetusreitin aktiivisuutta. Työn aikana onnistuttiin eristämään ja osittain tunnistamaan useita kuusen suspensioliuoksen yhdisteitä. Myo-inositolihapetusreitti todettiin aktiiviseksi solukkokasvatuksessa, kun ravintoalustassa on myo-inositolia.